Famar — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Famar is a well-established, privately-held Italian CDMO with a strong European footprint and a legacy spanning over seven decades. The company offers end-to-end services for pharmaceutical and consumer care products, specializing in a broad array of dosage forms including complex generics and high-potency APIs (HPAPIs). With approximately 1,800 employees and a portfolio of over 1,800 SKUs, Famar is a significant player in the outsourced pharmaceutical manufacturing sector, focusing on operational excellence and long-term customer partnerships.

Drug DeliverySmall Molecules

Technology Platform

Broad pharmaceutical development and manufacturing platform covering solid doses, liquids, semi-solids, sterile injectables, nasal sprays, ophthalmics, and HPAPI handling. Utilizes Quality by Design (QbD) and supports EMA/FDA regulatory pathways.

Opportunities

The growing trend of pharmaceutical outsourcing, especially for complex molecules like HPAPIs, presents a significant opportunity.

Expansion of the consumer health and wellness market also offers a parallel growth avenue for its topical product expertise.

Risk Factors

Key risks include operational/quality failures at manufacturing sites, client concentration, intense competition in the CDMO sector pressuring margins, and exposure to European regulatory and economic volatility.

Competitive Landscape

Famar competes in a crowded European CDMO market against large global players (e.g., Lonza, Catalent) and numerous regional specialists. Its differentiation lies in its broad dosage form expertise, long-standing legacy, and specific capabilities in complex generics and HPAPI manufacturing.

More companies in Small Molecule Drugs →More companies in Italy →